Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

64.50USD
26 May 2017
Change (% chg)

$-0.06 (-0.09%)
Prev Close
$64.56
Open
$64.37
Day's High
$64.75
Day's Low
$64.31
Volume
4,021,883
Avg. Vol
9,222,108
52-wk High
$88.85
52-wk Low
$63.88

GILD.O

Chart for GILD.O

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $84,283.98
Shares Outstanding(Mil.): 1,306.73
Dividend: 0.52
Yield (%): 3.22

Financials

  GILD.O Industry Sector
P/E (TTM): 6.82 137.90 17.41
EPS (TTM): 9.46 -- --
ROI: 29.63 -8.48 -5.42
ROE: 74.69 -11.31 -4.68

BRIEF-Gilead says stockholders did not approve proposal requesting board take steps to adopt policy that chairman of board be independent director

* Gilead-Stockholders did not approve proposal requesting board take steps to adopt policy that chairman of board be independent director-sec filing Source text (http://bit.ly/2r9rtBo) Further company coverage:

May 12 2017

Gilead profit falls as hepatitis C sales drop, shares down

Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2.5 percent.

May 02 2017

UPDATE 2-Gilead profit falls as hepatitis C sales drop, shares down

May 2 Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2.5 percent.

May 02 2017

Gilead net profit falls 25 percent on lower hepatitis C sales

May 2 Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2 percent.

May 02 2017

BRIEF-Galapagos announces new phase 2 proof-of-concept study with filgotinib

* Galapagos announces new phase 2 proof-of-concept study with filgotinib in cutaneous lupus erythematosus

Apr 25 2017

NASH: The next untapped pharma market gives investors many options

Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. | Video

Apr 24 2017

UPDATE 1-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 24 2017

RPT-INSIGHT-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 24 2017

INSIGHT-NASH: The next untapped pharma market gives investors many options

April 24 Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.

Apr 24 2017

BRIEF-Gilead announces results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations

* Results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations

Apr 21 2017

More From Around the Web

Earnings vs. Estimates